Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus

Research output: Contribution to journalReviewResearchpeer-review

  1. Integration af specialiseret palliation og onkologi

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Formodet SARS-CoV-2-dødsfald hos en tidligere rask 50-årig mand

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Akut luftvejsobstruktion grundet uerkendt akalasi efter ukompliceret vaginal fødsel

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Dansk Kvalitetsdatabase for Nyfødte (DKN) -resumé af årsrapport 2018. Indikator 9: antibiotikabehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Lokalanæstesitorakoskopi ved udredning af recidiverende pleuraeffusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Experience of family function, family involvement, and self-management in adult patients with type 2 diabetes: A thematic analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.
Translated title of the contribution[GLP-1-based treatment of type 2 diabetes mellitus]
Original languageDanish
JournalUgeskrift for Laeger
Volume169
Issue number22
Pages (from-to)2095-9
Number of pages5
Publication statusPublished - 28 May 2007

ID: 32267871